Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study.
Most adults stopped semaglutide for obesity within a year, with early discontinuation linked to socioeconomic factors.
This population-based retrospective cohort study examined early treatment trajectory and long-term persistence to semaglutide for obesity: a population-based cohort study. The PubMed abstract reports among 34,309 adults using semaglutide for obesity, discontinuation reached 676% by one year and was associated with socioeconomic and early-treatment factors.
What the study was
- Study design
- Population-based retrospective cohort study
- Population
- Adults without diabetes initiating semaglutide for obesity
- Sample size
- 28
- Category
- Public Health
- Maturity
- Validated
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Score reflects the population-based retrospective cohort study design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.